tarenflurbil has been researched along with ibuprofen, (r)-isomer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allegretti, M; Berdini, V; Bertini, R; Bizzarri, C; Cesta, MC; Colotta, F; Di Bello, N; Di Bitondo, R; Di Cioccio, V; Fantucci, P; Florio, S; Galliera, E; Locati, M; Nano, G; Nicolini, L; Russo, V; Topai, A; Zampella, G | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
2 other study(ies) available for tarenflurbil and ibuprofen, (r)-isomer
| Article | Year |
|---|---|
2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Chemokines, CXC; Chemotaxis, Leukocyte; Female; Humans; Ketoprofen; Ligands; Lymphoma; Macrophages, Peritoneal; Mice; Models, Molecular; Mutagenesis, Site-Directed; Propionates; Receptors, Interleukin-8A; Recombinant Proteins; Structure-Activity Relationship | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |